At a glance
ClinicalIndex Comparison RecordPhase 2Active· 22 enrolled
Drug / intervention
Copanlisib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol Z1G: Phase II Study of Copanlisib in Patients With Tumors With PTEN Loss by IHC and Any PTEN Sequencing Result
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 2 other interventions for Malignant Solid Neoplasm. Active but no longer recruiting, targeting 22 participants across 1 site.
Detailed Summary
The phase II MATCH treatment trial tests how well copanlisib works to treat patients with cancer with PTEN loss. Copanlisib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Solid Neoplasm
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
201920202021202220232024202520262027
Enrollment StartOct 2018
Primary CompletionJan 2023
First PostedApr 2024
TodayJul 2026
Study CompletionJan 2027
First PostedApr 11, 2024
Enrollment StartOct 8, 2018
Primary CompletionJan 5, 2023
Study CompletionJan 15, 2027
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 2.2 years ago
Interventions
Biopsy Procedureprocedure
Undergo tumor biopsy
Biospecimen Collectionprocedure
Undergo blood sample collection
Copanlisibdrug
Given IV
Radiologic Examinationprocedure
Undergo radiologic evaluation